Novel microRNA-based assay demonstrates 92 agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary

摘要

BackgroundCancer of unknown or uncertain primary is a major diagnostic and clinical challenge, since identifying the tissue-of-origin of metastases is crucial for selecting optimal treatment. MicroRNAs are a family of non-coding, regulatory RNA molecules that are tissue-specific, with a great potential to be excellent biomarkers.